Brain-Derived Neurotrophic Factor (BDNF) is the most abundant neurotrophin in the central nervous system and plays critical roles in neuronal survival, synaptic plasticity, neurogenesis, and cognitive function. BDNF signaling dysfunction is implicated in Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's Disease (HD). The BDNF-TrkB signaling axis represents a major therapeutic target for neurodegenerative disorders[1].
BDNF belongs to the neurotrophin family, which also includes Nerve Growth Factor (NGF), Neurotrophin-3 (NT-3), and Neurotrophin-4 (NT-4). Unlike NGF which is primarily peripheral, BDNF is highly expressed in the brain and is essential for central nervous system development and function.
| Component | Type | Function |
|---|---|---|
| BDNF | Neurotrophin | Primary ligand for TrkB[1:1] |
| Pro-BDNF | Precursor | Ligand for p75NTR, promotes apoptosis[2] |
| tPA | Protease | Converts pro-BDNF to mature BDNF[3] |
| Plasmin | Protease | Processes pro-BDNF[2:1] |
| TrkB | Receptor | Tyrosine kinase receptor for BDNF[3:1] |
| p75NTR | Receptor | Pan-neurotrophin receptor[4] |
| PI3K | Kinase | Akt pathway activation[5] |
| PLCγ | Enzyme | Phospholipase C gamma[3:2] |
| MAPK/ERK | Kinase pathway | Cell survival and differentiation[3:3] |
| CREB | Transcription factor | Gene expression[6] |
| mTOR | Kinase | Protein synthesis, synaptic plasticity[7] |
BDNF is synthesized as a precursor (pro-BDNF, 32 kDa) that can be:
The balance between pro-BDNF and mature BDNF is critical for neuronal health[2:2]:
Tissue plasminogen activator (tPA) is crucial for BDNF processing:
Upon BDNF binding, TrkB dimerizes and autophosphorylates tyrosine residues, activating three major pathways[5:1]:
PI3K/Akt Pathway:
PLCγ Pathway:
MAPK/ERK Pathway:
The p75NTR receptor can signal independently or in concert with Trk receptors:
Multiple mechanisms contribute to BDNF deficiency in AD[1:2]:
BDNF reduction: AD brains show decreased BDNF in hippocampus and cortex. Levels correlate with cognitive decline severity.
TrkB impairment: Amyloid-beta oligomers inhibit TrkB signaling, impairing synaptic plasticity[8]. Aβ directly interferes with TrkB autophosphorylation.
Pro-BDNF accumulation: Altered processing leads to pro-BDNF accumulation, promoting apoptosis and synaptic pruning.
Amyloid-BDNF interaction: Aβ may interfere with BDNF trafficking and signaling[9].
tPA/plasmin deficiency: Aβ inhibits tPA activity, reducing BDNF processing.
| Approach | Mechanism | Status |
|---|---|---|
| BDNF delivery | Exogenous BDNF protein | Preclinical |
| TrkB agonists | Activate TrkB signaling | Clinical trials[10] |
| Small molecule BDNF mimetics | Mimic BDNF effects | Preclinical |
| Gene therapy | AAV-BDNF | Phase 1/2 trials |
| tPA enhancement | Increase BDNF processing | Research |
The BDNF Val66Met polymorphism affects[11]:
BDNF is essential for dopaminergic neuron survival in the substantia nigra[12]:
Nigral BDNF decline: PD substantia nigra shows reduced BDNF expression. This precedes dopaminergic neuron loss.
TrkB in survival: BDNF supports dopaminergic neuron survival and function through PI3K/Akt pathway.
α-Syn interaction: Alpha-synuclein may impair BDNF trafficking and signaling.
Therapeutic approaches: BDNF gene therapy has been explored in PD models[13].
BDNF signaling affects mitochondrial dynamics:
BDNF deficiency is a central feature of HD[14]:
BDNF reduction: Mutant huntingtin impairs BDNF transcription in cortical neurons. Reduced cortical output contributes to striatal vulnerability.
BDNF transport: mHTT disrupts BDNF trafficking along corticostriatal projections.
TrkB signaling: Altered downstream signaling pathways.
Therapeutic potential: Enhancing BDNF signaling is a key HD therapeutic strategy.
BDNF plays critical roles in ALS[4:1]:
Motor neuron survival: BDNF supports motor neuron viability.
Clinical trials: BDNF delivery trials in ALS showed some promise but faced challenges with delivery across blood-brain barrier.
TrkB signaling: Preserving TrkB signaling may slow disease progression.
SOD1 mutations: Affect BDNF retrograde transport.
BDNF has significant metabolic effects[15]:
BDNF promotes adult hippocampal neurogenesis[16]:
BDNF affects microglial function[17]:
Exercise is a potent BDNF inducer[18]:
| Measure | Source | Disease | Utility |
|---|---|---|---|
| BDNF levels | Serum/Plasma | AD, PD | Progression marker |
| Pro-BDNF | CSF | AD | Disease severity |
| BDNF/Pro-BDNF ratio | CSF | AD | Diagnostic |
| Val66Met genotype | Blood DNA | AD | Risk stratification |
| Agent | Target | Phase | Status |
|---|---|---|---|
| BDNF protein | TrkB | Preclinical | Ongoing |
| 7,8-DHF | TrkB agonist | Phase 1 | Recruiting |
| AAV-BDNF | BDNF | Phase 1/2 | Ongoing |
| Exercise intervention | Endogenous BDNF | Various | Active |